Handelsbanken Fonder AB Has $45.17 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Handelsbanken Fonder AB lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 538,703 shares of the biopharmaceutical company’s stock after selling 10,722 shares during the quarter. Handelsbanken Fonder AB’s holdings in Gilead Sciences were worth $45,165,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Wright Investors Service Inc. boosted its position in shares of Gilead Sciences by 19.9% during the 3rd quarter. Wright Investors Service Inc. now owns 64,123 shares of the biopharmaceutical company’s stock valued at $5,376,000 after purchasing an additional 10,631 shares in the last quarter. Mirador Capital Partners LP lifted its stake in Gilead Sciences by 3.5% in the third quarter. Mirador Capital Partners LP now owns 13,195 shares of the biopharmaceutical company’s stock valued at $1,106,000 after buying an additional 443 shares during the period. Farmers Trust Co. boosted its holdings in shares of Gilead Sciences by 3.7% during the 3rd quarter. Farmers Trust Co. now owns 65,004 shares of the biopharmaceutical company’s stock worth $5,450,000 after buying an additional 2,306 shares in the last quarter. Curbstone Financial Management Corp acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $473,000. Finally, Czech National Bank grew its position in shares of Gilead Sciences by 6.8% during the 3rd quarter. Czech National Bank now owns 253,618 shares of the biopharmaceutical company’s stock worth $21,263,000 after buying an additional 16,209 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,847 shares of company stock worth $3,033,340. 0.16% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

Shares of GILD stock traded up $0.42 during trading on Friday, hitting $84.59. The company’s stock had a trading volume of 4,054,354 shares, compared to its average volume of 7,221,453. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The company has a market cap of $105.39 billion, a PE ratio of 234.97, a P/E/G ratio of 2.91 and a beta of 0.18. The business has a fifty day moving average of $79.06 and a 200-day moving average of $71.91. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.64%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Truist Financial increased their target price on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target on the stock in a report on Monday, July 8th. BMO Capital Markets boosted their price objective on Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $70.00 target price on shares of Gilead Sciences in a report on Monday, September 16th. Twelve research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $82.12.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.